Incentive to study drugs in children and other governmental initiatives: Will patients with asthma benefit?

被引:5
作者
Giacoia, GP
机构
[1] NICHHD, Pediat Pharmacol Res Unit Network, Bethesda, MD 20892 USA
[2] Georgetown Univ, Dept Pediat, Washington, DC 20057 USA
关键词
pediatric drug trials; pediatric labeling; Pediatric Pharmacology Research Unit Network; Pediatric Rule of 1998; biomarkers;
D O I
10.1067/mai.2000.109417
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
This article summarizes current regulations that have been developed to facilitate the performance of pediatric drug trials and their impact on children, particularly those children affected with asthma, in addition, other initiatives that have been developed by the federal government in response to the unexplained increase of asthma occurrence during the last 15 years will be reviewed. In the face of an asthma epidemic, a comprehensive approach is needed to determine the causes for the increase in the prevalence rate and the role of aeroallergens and other environmental and genetic factors and to identify effective preventive measures. Clearly, facilitating drug trials to prove the safety and effectiveness of drugs is of paramount importance.
引用
收藏
页码:S118 / S124
页数:7
相关论文
共 30 条
[21]   EDITORIAL COMMENT - THERAPEUTIC ORPHANS [J].
SHIRKEY, H .
JOURNAL OF PEDIATRICS, 1968, 72 (01) :119-+
[22]  
TAYLOR WR, 1992, PEDIATRICS, V90, P657
[23]  
*US DEP HHS, 1999, ACT ASTHM STRAT PLAN
[24]   AN ECONOMIC-EVALUATION OF ASTHMA IN THE UNITED-STATES [J].
WEISS, KB ;
GERGEN, PJ ;
HODGSON, TA .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) :862-866
[25]  
Weiss Scott T., 1994, Comprehensive Therapy, V20, P606
[26]   Gene by environment interaction and asthma [J].
Weiss, ST .
CLINICAL AND EXPERIMENTAL ALLERGY, 1999, 29 :96-98
[27]  
WILSON JT, 1972, J PEDIATR-US, V80, P855
[28]  
WOOLCOCK AJ, 1997, EVIDENCE INCREASE AS, P122
[29]  
YUNNINGER JW, 1992, AM REV RESPIR DIS, V146, P888
[30]  
1998, FED REG 277733, V63